As competitive as the obesity drug market has become, Novo Nordisk's decision to slash the prices of its GLP-1 agonist drugs ...
Studies from Novo Nordisk due early next month will give the strongest indication yet of whether blockbuster GLP-1 drugs - a ...
Novo Nordisk's discounted valuations and promising oral candidate may trigger a drastic reversal in its stock ...
Danish drugmaker Novo Nordisk A/S was at the forefront of the weight-loss injection boom as people discovered that its ...
Novo Nordisk A/S faces intensifying GLP-1 competition, notably from Eli Lilly, prompting price cuts for Wegovy. Learn more ...
Until the end of March, Novo Nordisk will let people with prescriptions buy the first two doses of the drugs for $199 a month ...
Novo Nordisk said on Monday it has begun selling its popular weight-loss drug Wegovy for $349 a month to cash payers, months ...
The Danish drugmaker said it's cutting the price of Wegovy and Ozempic from $499 to $349 per month for some customers who buy ...
Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and ...
1don MSN
Zepbound maker Eli Lilly hits $1T market cap — becoming first drug company to reach milestone
A more than 35% rally in the company’s stock this year has largely been driven by the explosive growth of the weight-loss ...
New cash-paying patients can now access Wegovy/Ozempic for $199 a month. Here's what that means for Novo Nordisk stock.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback